DE69636450D1 - PEPTIDE UND PEPTIDOMIMETIKA MIT STRUKTURELLER ÄHNLICHKEIT MIT p53 UND DIE DIE p53-FUNKTION AKTIVIEREN - Google Patents

PEPTIDE UND PEPTIDOMIMETIKA MIT STRUKTURELLER ÄHNLICHKEIT MIT p53 UND DIE DIE p53-FUNKTION AKTIVIEREN

Info

Publication number
DE69636450D1
DE69636450D1 DE69636450T DE69636450T DE69636450D1 DE 69636450 D1 DE69636450 D1 DE 69636450D1 DE 69636450 T DE69636450 T DE 69636450T DE 69636450 T DE69636450 T DE 69636450T DE 69636450 D1 DE69636450 D1 DE 69636450D1
Authority
DE
Germany
Prior art keywords
peptidomimetics
peptides
activate
function
structural similarity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636450T
Other languages
English (en)
Other versions
DE69636450T2 (de
Inventor
Thanos Halazonetis
Wolfgang Hartwig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Wistar Institute of Anatomy and Biology
Original Assignee
Bayer Corp
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp, Wistar Institute of Anatomy and Biology filed Critical Bayer Corp
Publication of DE69636450D1 publication Critical patent/DE69636450D1/de
Application granted granted Critical
Publication of DE69636450T2 publication Critical patent/DE69636450T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
DE69636450T 1995-02-16 1996-02-16 PEPTIDE UND PEPTIDOMIMETIKA MIT STRUKTURELLER ÄHNLICHKEIT MIT p53 UND DIE DIE p53-FUNKTION AKTIVIEREN Expired - Lifetime DE69636450T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/392,542 US6169073B1 (en) 1995-02-16 1995-02-16 Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US392542 1995-02-16
PCT/US1996/001535 WO1996025434A1 (en) 1995-02-16 1996-02-16 PEPTIDES AND PEPTIDOMIMETICS WITH STRUCTURAL SIMILARITY TO HUMAN p53 THAT ACTIVATE p53 FUNCTION

Publications (2)

Publication Number Publication Date
DE69636450D1 true DE69636450D1 (de) 2006-09-28
DE69636450T2 DE69636450T2 (de) 2007-05-03

Family

ID=23550993

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636450T Expired - Lifetime DE69636450T2 (de) 1995-02-16 1996-02-16 PEPTIDE UND PEPTIDOMIMETIKA MIT STRUKTURELLER ÄHNLICHKEIT MIT p53 UND DIE DIE p53-FUNKTION AKTIVIEREN

Country Status (10)

Country Link
US (6) US6169073B1 (de)
EP (1) EP0809655B1 (de)
JP (1) JP3980055B2 (de)
KR (1) KR100598744B1 (de)
AT (1) ATE336511T1 (de)
AU (1) AU718963B2 (de)
CA (1) CA2213229C (de)
DE (1) DE69636450T2 (de)
ES (1) ES2271950T3 (de)
WO (1) WO1996025434A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
GB9521544D0 (en) * 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
WO1998006753A2 (en) * 1996-08-13 1998-02-19 Trustees Of Princeton University P53 mutant
AU7238098A (en) * 1997-05-15 1998-12-08 Kyowa Hakko Kogyo Co. Ltd. Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6767889B1 (en) * 1998-11-10 2004-07-27 Temple University Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof
WO2000064934A1 (en) * 1999-04-23 2000-11-02 Research Corporation Technologies, Inc. Therapeutic compositions and methods for treating tumors
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
GB0011439D0 (en) * 2000-05-12 2000-06-28 Novartis Res Found Cancer diagnosis and assays for screening
US7196242B2 (en) * 2000-05-16 2007-03-27 The Regents Of The University Of California Methods for identifying novel therapeutics and diagnostics in the p53 pathway
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6989239B2 (en) * 2001-06-20 2006-01-24 R.E.D. Laboratories, N.V./S.A. Methods for diagnosis and treatment of chronic immune diseases
US20050032060A1 (en) * 2001-08-31 2005-02-10 Shishir Shah Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
AU2003205830A1 (en) 2002-01-23 2003-09-02 Mohamed Raafat El-Gewely Molecular libraries
US6916621B2 (en) * 2002-03-27 2005-07-12 Spectral Genomics, Inc. Methods for array-based comparitive binding assays
PL376536A1 (pl) 2002-08-28 2006-01-09 Immunex Corporation Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
WO2005002526A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Method and compositions for treatment of viral infections
EP1648935A2 (de) 2003-07-25 2006-04-26 Amgen Inc. Antagonisten und agonisten von ldcam und anwendungsverfahren
US7109852B2 (en) * 2004-01-28 2006-09-19 Lear Corporation Vehicle occupancy intruder security system
WO2005074521A2 (en) * 2004-01-30 2005-08-18 The Trustees Of Columbia University In The City Of New York C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF
WO2007149062A2 (en) 2005-03-14 2007-12-27 Board Of Regents, The University Of Texas System Bioactive fus1 peptides and nanoprticle-polypeptide complexes
KR100749858B1 (ko) * 2005-08-12 2007-08-16 연세대학교 산학협력단 ｐ53 변이체 및 그의 용도
WO2008064401A1 (en) * 2006-11-28 2008-06-05 Alzhyme Pty Ltd Improved peptide composition
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
WO2008076904A1 (en) 2006-12-14 2008-06-26 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
JP4997293B2 (ja) 2007-02-23 2012-08-08 エイルロン セラピューティクス，インコーポレイテッド トリアゾール大環状系
KR20160061439A (ko) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US9539327B2 (en) * 2007-11-26 2017-01-10 The Research Foundation For The State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CN102256615A (zh) 2009-01-14 2011-11-23 爱勒让治疗公司 拟肽大环化合物
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
AU2011248614B2 (en) 2010-04-27 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
EP2563383B1 (de) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CA2797977C (en) 2010-05-03 2019-08-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
EP2566499B1 (de) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten aus einem p38-multi-trna-synthetase-komplex
EP3023496B1 (de) 2010-05-13 2020-07-29 Sarepta Therapeutics, Inc. Verbindungen, die die signalaktivität von interleukin-17- und interleukin-23 modulieren
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103118695B (zh) 2010-07-12 2016-08-03 Atyr医药公司 与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
EP2608801B1 (de) 2010-08-25 2019-08-21 aTyr Pharma, Inc. Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von tyrosyl-trna-synthetasen
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 ***交联的和硫醚交联的拟肽大环化合物
CN107216380A (zh) 2012-02-15 2017-09-29 爱勒让治疗公司 拟肽大环化合物
ES2652136T3 (es) 2012-02-16 2018-01-31 Atyr Pharma, Inc. Histidil-tRNA sintetasas para tratar enfermedades autoinmunitarias e inflamatorias
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
CN110478481A (zh) 2013-03-13 2019-11-22 比奥阿赛斯技术有限公司 p97片段及其应用
CA2920147C (en) 2013-08-07 2022-09-20 Yeda Research And Development Co. Ltd. Peptides capable of reactivating p53 mutants
KR20220147691A (ko) 2013-08-09 2022-11-03 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
EP3294318A4 (de) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen und verwendungen davon
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
WO2017134671A1 (en) 2016-02-04 2017-08-10 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
US20220162336A1 (en) 2018-07-22 2022-05-26 Bioasis Technologies, Inc. Treatment of lymphatic metastases
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2020070021A1 (en) 2018-10-04 2020-04-09 Koninklijke Philips N.V. Fluid flow detection for ultrasound imaging devices, systems, and methods
WO2021072056A1 (en) * 2019-10-08 2021-04-15 Portage Glasgow Limited P53 peptide disrupters of f0x04:p53 protein binding, variants and conjugates thereof.
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
US20230108717A1 (en) * 2021-10-05 2023-04-06 The Penn State Research Foundation Novel methods of creating a protein map and using said map to identify therapeutic targets

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362623A (en) 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
CA2124595A1 (en) 1992-09-30 1994-04-14 Hanswalter Zentgraf Process for detecting p53-specific antibodies
FR2698367B1 (fr) 1992-11-02 1995-02-17 Eurobio Lab Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
GB9224784D0 (en) 1992-11-26 1993-01-13 Univ Dundee Cellular protein
WO1995017213A1 (en) 1993-12-21 1995-06-29 Sloan-Kettering Institute For Cancer Research P53-based polypeptide fragments, nucleic acid molecules encoding same, and uses thereof
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function

Also Published As

Publication number Publication date
US6245886B1 (en) 2001-06-12
US6784157B2 (en) 2004-08-31
ATE336511T1 (de) 2006-09-15
JPH11500311A (ja) 1999-01-12
AU4915096A (en) 1996-09-04
US6169073B1 (en) 2001-01-02
AU718963B2 (en) 2000-05-04
US6420118B1 (en) 2002-07-16
JP3980055B2 (ja) 2007-09-19
ES2271950T3 (es) 2007-04-16
CA2213229C (en) 2014-10-14
DE69636450T2 (de) 2007-05-03
US20070167611A1 (en) 2007-07-19
US20030124557A1 (en) 2003-07-03
CA2213229A1 (en) 1996-08-22
US20030171537A1 (en) 2003-09-11
US7666983B2 (en) 2010-02-23
KR19980702283A (ko) 1998-07-15
KR100598744B1 (ko) 2006-09-22
EP0809655B1 (de) 2006-08-16
WO1996025434A1 (en) 1996-08-22
US7189801B2 (en) 2007-03-13
EP0809655A1 (de) 1997-12-03

Similar Documents

Publication Publication Date Title
DE69636450D1 (de) PEPTIDE UND PEPTIDOMIMETIKA MIT STRUKTURELLER ÄHNLICHKEIT MIT p53 UND DIE DIE p53-FUNKTION AKTIVIEREN
GR3034332T3 (en) Protein purification.
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
CA2172376A1 (en) Antibodies to cd40
HUP0000302A2 (hu) OB fúziós protein készítmények és módszerek
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
AU676859B2 (en) Synthetic peptides, antibodies against them and their use
AU5229498A (en) Mutants of the lag-3 proteins, products for the expression of these mutants and use
ATE397062T1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
ES2172044T3 (es) Supresion de la proliferacion de celulas t usando fragmentos peptidicos de proteina basica de mielina.
ZA965565B (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits.
WO2000053742A3 (en) Polynucleotides and proteins encoded thereby
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
WO1999022005A3 (en) Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor
WO2000061754A3 (en) Human proteins and polynucleotides encoding them
DE68914397D1 (de) Menschliches Lymphotoxin.
WO2000070046A3 (en) Secreted polypeptides and corresponding polynucleotides
WO1999031229A3 (en) Peptides and nucleic acids derived from eisenia foetida and the use thereof
CA2140091A1 (en) Peptides and antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2
WO2001023561A3 (en) Novel polynucleotides encoding proteins containing thrombospondin type 1 repeats
WO2002014348A3 (en) Glycoproteins and methods of use thereof
WO2001019856A3 (en) Secreted human proteins, polynucleotides encoding them and methods of using the same

Legal Events

Date Code Title Description
8364 No opposition during term of opposition